Do you want to read an article? Please log in or register.
Activin signaling inhibitors in the treatment landscape of pulmonary arterial hypertension
Pulmonary Hypertension
ERS 2024
Related content
RECOMMENDED
Pulmonary Hypertension
Low nailfold capillary density in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: biomarker of clinical outcome?
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Sci Rep
Smits AJ, Isebia K, Combee-Duffy C, van der Wal S, Nossent EJ, Boonstra A, Vonk-Noordegraaf A, Bogaard HJ, Serné EH
doi: 10.1038/s41598-024-69017-y
Pulmonary Hypertension
Clinical Characteristics and Treatment of Patients Diagnosed with Pulmonary Arterial Hypertension: A Real-World Study in the USA, Europe and Japan
Adv Ther
Vizza CD, Klok R, Harley J, Small M, Scott M, Lautsch D, White RJ
doi: 10.1007/s12325-024-03026-1
Pulmonary Hypertension
Global, regional, and national burden of pulmonary arterial hypertension, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021
Lancet Respir Med
GBD 2021 Pulmonary Arterial Hypertension Collaborators
doi: 10.1016/S2213-2600(24)00295-9
RECOMMENDED
Pulmonary Hypertension
Safety and efficacy of riociguat in patients with pulmonary arterial hypertension and cardiometabolic comorbidities: Data from interventional clinical trials
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
J Heart Lung Transplant
Rosenkranz S, Ghofrani HA, Hoeper MM, Langleben D, Hegab S, Rahner C, Richard JF, McLaughlin VV
doi: 10.1016/j.healun.2024.08.018
RECOMMENDED
Pulmonary Hypertension
Consistent Safety and Efficacy of Sotatercept for Pulmonary Arterial Hypertension in BMPR2 Mutation Carriers and Noncarriers: A Planned Analysis of Phase 2, Double-Blind, Placebo-controlled Clinical Trial (PULSAR)
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Am J Respir Crit Care Med
Montani D, McLaughlin VV, Gibbs JSR, Gomberg-Maitland M, Hoeper MM, Preston IR, Souza R, Waxman AB, Escribano Subias P, Feldman J, Meyer GM, Olsson KM, Coulet F, Manimaran S, Zhao Y, Lau A, de Oliveira Pena J, Badesch DB, Humbert M
doi: 10.1164/rccm.202409-1698OC
COMMENTED
Pulmonary Hypertension
Effects of β-blockers on the Outcomes in Patients with Pulmonary Arterial Hypertension Stratified by the Presence of Comorbid Conditions: a Multicenter Prospective Cohort Study (BNP-PL)
★ 3
Recommended and commented by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Chest
Waligóra M, Kurzyna M, Mularek-Kubzdela T, Skoczylas I, Chrzanowski Ł, Błaszczak P, Jaguszewski M, Kuśmierczyk B, Ptaszyńska K, Grześk G, Mizia-Stec K, Malinowska E, Peregud-Pogorzelska M, Lewicka E, Tomaszewski M, Jacheć W, Florczyk M, Mroczek E, Gąsior Z, Pawlak A, Betkier-Lipińska K, Pruszczyk P, Widejko K, Zabłocka W, Kopeć G
doi: 10.1016/j.chest.2024.10.051
Pulmonary Hypertension
Study of Angiogenic Cell Therapy for Progressive Pulmonary Arterial Hypertension: Intervention with Repeat Dosing of eNOS-enhanced EPCs: the SAPPHIRE Trial
J Heart Lung Transplant
Stewart DJ, Mehta S, Chandy G, Hirani N, Granton J, Hambly N, Swiston J, Danovitch K, Sabri E, Giulivi A, Courtman DW, Fergusson DA
doi: 10.1016/j.healun.2025.05.012
Pulmonary Hypertension
Long-Term Mortality and Morbidity Impact on Patients with Pulmonary Arterial Hypertension (PAH) If Access to Sotatercept Is Delayed: A Simulation Model
Adv Ther
Alsumali A, McLaughlin V, Chevure J, Klok R, Zhang W, Martinez EC, Pausch C, De Oliveira Pena J, van de Wetering G, Jootun M, Lautsch D, Hoeper MM
doi: 10.1007/s12325-025-03241-4
Pulmonary Hypertension
Halofuginone prevents inflammation and proliferation of high-altitude pulmonary hypertension by inhibiting the TGF-β1/Smad signaling pathway
Sci Rep
Wang J, Guan L, Yu J, Ma B, Shen H, Xing G, Xu Y, Li Q, Liu J, Xu Q, Shi W, He J, Huang Y, Yin D, Li W, Wang R
doi: 10.1038/s41598-025-88258-z